E Pharma And Religion

Tuesday saw Wall Street anxious to avoid a 2nd down day in a row despite politics and health issues. Trump in his first press briefing since the attack on Capitol Hill claimed his remarks to the mobs of his followers was “totally appropriate”. He also claimed that Congressional attempts to impeach him were “causing tremendous anger”, according to a note from the New York Times. He fanned the flames again.

Retail sales fell sharply in Britain and took down stock markets.

Business newspaper article

image source

Pharma and Religion

*The European Medicines Agency got a conditional marketing authorization application from AZNAstraZeneca for the COVID-19 vaccine it developed with Oxford University. The decision on permitting use will be made by Jan. 29 after a review by CHMP. The European Commission will then fast-track its decision-making process, aiming to grant a conditional marketing authorization "within days," the EMA said. The news came after AZN stock fell in London. More below.

*Glaxo GSK and partner Vir will test VIR:782 COVID-19 antibodies in UK patients with mild to moderate infection in a phase I-II trial authorized by British AGILE, which uses advanced statistics on drug trials. VIR-782 is an antibody that enhances both clearing of infected cells and T-cell function. This is their 2nd monoclonal antibody trial after they messed up an earlier trial with bad data collection. Glaxo shares also fell in London.

*Beigene BGNE opened up 8% to $304 but fell to $299.82 84.84 today, up about 5%. BGNE's cancer drug Tislelzumab, an anti-PD1 monoclonal antibody that binds to CcyR on macrophages, was licensed to NVS, Swiss Novartis NVS.

*Fellow Swiss Roche reported enhanced survival in phase III trials of Tecentriq with Avastin in resectable liver cancers, compared to Bayer's Nexavax, cutting deaths by 34% and overall survival of 19.2 months vs 11.4% months with the Bayer drug. RHHBY.

*Danish Novo Nordisk NVO presented at the JP Morgan Healthcare conference and there may be a nice write-up tomorrow I can quote on Thursday. No blog Weds. as I am getting my COVID-19 jab. 

*Abcellera ABCL is up 9.4%% today to $40+ but is still down 21% from our basis.

1 2 3 4
View single page >> |
How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.